Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL903703 | 1.00 | CYP3A4 (0.75) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL3265289 | 1.00 | CYP3A4 (0.75) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL8751564 | 1.00 | CYP3A4 (0.75) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL14979709 | 0.92 | CYP3A4 (0.65) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL17615404 | 0.92 | CYP3A4 (0.65) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL23004536 | 0.91 | CYP3A4 (0.64) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL6126244 | 0.91 | CYP3A4 (0.64) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL9941180 | 0.91 | CYP3A4 (0.62) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL9912032 | 0.91 | CYP3A4 (0.87) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL6121467 | 0.91 | CYP3A4 (0.62) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445367-B1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| EP-3778606-A2 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3431477-B1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10787441-B2 | Hepatitis C virus inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-09-29 | — | — | US | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| EP-2945952-B1 | HETEROCYCLE-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190127355-A1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| US-8575135-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575135-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013075029-A1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | CYP3A4 2443/4885CYP2C9 3743/4885NR1I2 3982/4885 |
| US-10787441-B2 | Hepatitis C virus inhibitors | HAVCR2, FABP1, SLC10A1 | CYP3A4 140/4885CYP2C9 245/4885NR1I2 110/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885NR1I2 2411/4885 |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | CYP3A4 2443/4885CYP2C9 3743/4885NR1I2 3982/4885 |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | CYP3A4 2443/4885CYP2C9 3743/4885NR1I2 3982/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CYP2C9 3296/4885NR1I2 3435/4885 |
| US-20190127355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, FABP1, SLC10A1 | CYP3A4 140/4885CYP2C9 245/4885NR1I2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.